Abstract: The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.

Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.

Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.

Abstract: A system for generating accessory power from a gas turbine engine is provided by the present invention. The system includes an electronic control device for monitoring at least one parameter which provides information about an incipient change in power demand, a control valve operated by the control device for supplying bleed air from the engine during a transient state in response to the at least one monitored parameter, and a pneumatically operated device for receiving the bleed air and for generating power to operate equipment onboard an aircraft. The pneumatically operated device may be an air turbine or a pneumatically integrated generator.

Abstract: A system for generating accessory power from a gas turbine engine is provided by the present invention. The system includes an electronic control device for monitoring at least one parameter which provides information about an incipient change in power demand, a control valve operated by the control device for supplying bleed air from the engine during a transient state in response to the at least one monitored parameter, and a pneumatically operated device for receiving the bleed air and for generating power to operate equipment onboard an aircraft. The pneumatically operated device may be an air turbine or a pneumatically integrated generator.

Abstract: A system for generating accessory power from a gas turbine engine is provided by the present invention. The system includes an electronic control device for monitoring at least one parameter which provides information about an incipient change in power demand, a control valve operated by the control device for supplying bleed air from the engine during a transient state in response to the at least one monitored parameter, and a pneumatically operated device for receiving the bleed air and for generating power to operate equipment onboard an aircraft. The pneumatically operated device may be an air turbine or a pneumatically integrated generator.